Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. is a publicly-traded biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer. The compounds result from internal chemistry efforts targeting the active sites of enzymes that are key drivers of tumor growth. Its highly targeted clinical development programs are focused on treating selected tumor types that express high levels or key driver mutations of these targets in order to most effectively address unmet patient needs. The lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. Mirati is also evaluating development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor for the treatment of patients with myelodysplastic syndrome and MGCD516, a unique kinase inhibitor with a distinct target profile for the treatment of patients with non-small cell lung cancer and other solid tumors. The company was founded on December 13, 1995 and is headquartered in Montréal, Canada.